Mirati’s lung cancer drug fails to win EU regulator’s backing
(Reuters) -Mirati Therapeutics said on Friday the European Medicines Agency’s panel had declined to back authorization for its drug to treat a type of lung cancer, sending the drugmaker’s shares down over 11% in early trading.
The EMA said the drugmake…